ArticleBMC cancer2026
Prognostic significance and optimal staging of supraclavicular lymph node metastasis in upper esophageal squamous cell carcinoma undergoing chemoradiotherapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe optimal staging of supraclavicular lymph node metastasis (SCLNM) in upper esophageal squamous cell carcinoma (UESCC) remains debated. This study aimed to evaluate its prognostic significance and clinical implications in patients treated with definitive chemoradiotherapy.
methodsThis study included 435 newly diagnosed UESCC patients who received definitive chemoradiotherapy between January 2013 and October 2022. Survival and prognostic factors were analyzed by Kaplan-Meier and Cox regression methods.
resultsSCLNM was diagnosed in 49 patients (11.3%) and was strongly associated with metastasis at stations 101, 106rec, 106pre, and 106tb. Multivariate analysis confirmed SCLNM as an independent prognostic factor. Patients with SCLNM had poorer survival than those with M0 disease but better than those with other distant metastases (median overall survival: 24.0 vs. 67.0 vs. 8.0 months). Survival was significantly lower in SCLNM patients compared to N0M0 (P < 0.001) and N1M0 (P = 0.004) patients, but no significant difference was observed compared to N2M0 (P = 0.477) or N3M0 (P = 0.204) patients. After reclassifying SCLNM as a regional lymph node metastasis, N1 patients with SCLNM exhibited worse overall survival than those without SCLNM, although the statistical significance was marginal (P = 0.048); however, this difference was not seen in N2 or N3 categories. In the revised staging system where SCLNM was assigned to N2 or higher, survival differentiation across stages became more distinct, yielding a higher prognostic accuracy compared to the current AJCC staging system.
conclusionsSCLNM in UESCC patients undergoing definitive CRT shows prognostic similarity to N2-3 disease, but this finding is preliminary and requires further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.